Who are Fludeoxyglucose PET CT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FLUDEOXYGLUCOSE F 18, [F-18]-Fludeoxyglucose, Fludeoxyglucose F 18 (FDG), 18F-2-fluoro-2-deoxy-D-glucose, strontium-89, Sr-89.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fludeoxyglucose-pet-ct.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fludeoxyglucose PET CT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fludeoxyglucose PET CT (Fludeoxyglucose PET CT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

phase 2 Radiopharmaceutical Glucose transporter Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fludeoxyglucose PET CT (Fludeoxyglucose PET CT) — Michael C Roarke, MD. A positron-emitting glucose analog that accumulates in cancer cells, allowing for PET imaging.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fludeoxyglucose PET CT TARGET	Fludeoxyglucose PET CT	Michael C Roarke, MD	phase 2	Radiopharmaceutical	Glucose transporter
FLUDEOXYGLUCOSE F 18	FLUDEOXYGLUCOSE F 18		marketed	Radioactive Diagnostic Agent [EPC]	glucose transporter proteins, hexokinase, glucose-6-phosphatase	1994-01-01
[F-18]-Fludeoxyglucose	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
18F-2-fluoro-2-deoxy-D-glucose	18F-2-fluoro-2-deoxy-D-glucose	Eastern Health, Canada	phase 3	Positron emission tomography (PET) imaging agent	Glucose transporter (GLUT1) and hexokinase
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

Amsterdam UMC, location VUmc · 1 drug in this class
Blue Earth Diagnostics · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
ITEL Telecomunicazioni Srl · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fludeoxyglucose PET CT — Competitive Intelligence Brief. https://druglandscape.com/ci/fludeoxyglucose-pet-ct. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing